Additionally, SHIP1 is a direct target of miR-155 expression which, in turn, is positively regulated by crosstalk within the lymphoid tissue microenvironment, such as CD154 or the B-cell activating factor (BAFF), enhancing the BCR signaling, promoting proliferation in cancer cells, and potentially contributing to its association with adverse clinical outcomes in patients with CLL. The gene discussed is BCR; the disease is B-cell chronic lymphocytic leukemia.